Brown Brothers Harriman & Co. Has $29,000 Stock Position in Sanofi (NASDAQ:SNY)

Brown Brothers Harriman & Co. lessened its position in Sanofi (NASDAQ:SNY) by 89.2% in the third quarter, according to its most recent disclosure with the SEC. The firm owned 500 shares of the company’s stock after selling 4,148 shares during the period. Brown Brothers Harriman & Co.’s holdings in Sanofi were worth $29,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Bank of New York Mellon Corp lifted its stake in shares of Sanofi by 19.0% in the second quarter. Bank of New York Mellon Corp now owns 8,594,740 shares of the company’s stock valued at $417,017,000 after buying an additional 1,370,232 shares in the last quarter. Barrow Hanley Mewhinney & Strauss LLC lifted its position in Sanofi by 113.8% in the 2nd quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 5,943,547 shares of the company’s stock valued at $288,381,000 after acquiring an additional 3,164,092 shares in the last quarter. Envestnet Asset Management Inc. boosted its stake in Sanofi by 8.2% during the 2nd quarter. Envestnet Asset Management Inc. now owns 3,252,326 shares of the company’s stock valued at $157,803,000 after purchasing an additional 246,224 shares during the last quarter. Federated Hermes Inc. raised its stake in shares of Sanofi by 26.5% in the second quarter. Federated Hermes Inc. now owns 3,214,141 shares of the company’s stock worth $155,950,000 after purchasing an additional 673,172 shares during the last quarter. Finally, Natixis Advisors LLC raised its stake in shares of Sanofi by 4.1% in the third quarter. Natixis Advisors LLC now owns 2,874,193 shares of the company’s stock worth $165,640,000 after purchasing an additional 114,133 shares during the last quarter. Institutional investors own 10.04% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on SNY shares. StockNews.com downgraded Sanofi from a “strong-buy” rating to a “buy” rating in a report on Thursday, November 7th. Citigroup raised shares of Sanofi to a “strong-buy” rating in a report on Tuesday, September 17th. Two research analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $57.50.

Sanofi Stock Performance

SNY stock opened at $48.72 on Friday. The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 0.17. The firm has a market cap of $123.64 billion, a PE ratio of 24.86, a P/E/G ratio of 1.22 and a beta of 0.61. The business has a 50 day moving average of $53.17 and a 200-day moving average of $52.15. Sanofi has a 12-month low of $45.22 and a 12-month high of $58.97.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings data on Friday, October 25th. The company reported $1.57 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.22 by $1.35. The firm had revenue of $13.44 billion during the quarter, compared to the consensus estimate of $16.59 billion. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. The business’s revenue for the quarter was up 12.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.55 EPS. As a group, sell-side analysts expect that Sanofi will post 4.29 earnings per share for the current year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.